(R)-2-(三氟甲基)哌啶 | 1212734-83-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (R)-2-(三氟甲基)哌啶
• 英文名称: (R)-2-(trifluoromethyl)piperidine
• 英文别名: (2R)-2-(trifluoromethyl)piperidine
• CAS: 1212734-83-2
• 化学式: C₆H₁₀F₃N
• mdl: MFCD11226598
• 分子量: 153.147
• InChiKey: NAXDEFXCCITWEU-RXMQYKEDSA-N

物化性质

• 密度：
  1.170 g/mL at 25 °C
• 闪点：
  27℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• WGK Germany：
  3
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  (R)-2-(三氟甲基)哌啶 在 四(三苯基膦)钯 吡啶 、 potassium phosphate 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 methyl 2-(4-fluorophenyl)-3-[(2R)-2-(trifluoromethyl)piperidin-1-yl]quinoxaline-6-carboxylate
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
  [FR] COMPOSÉS HÉTÉROCYCLIQUES POUR L'INHIBITION DE LA KINASE DE DOMAINE PAS (PASK)

  摘要：

  公开号：

  WO2012119046A3

文献信息

• HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
  申请人：McCall John M.

  公开号：US20120232056A1

  公开（公告）日：2012-09-13

  Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

  本文披露了新的杂环化合物和组合物，并将其应用作药物治疗疾病。还提供了抑制人类或动物主体中PAS激酶（PASK）活性的方法，以治疗糖尿病等疾病。
• Quinoline derivatives
  申请人：Gilead Sciences, Inc.

  公开号：US11116760B2

  公开（公告）日：2021-09-14

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

  本公开提供了一种式 (I) 的化合物： 或其药学上可接受的盐。本公开还提供了包含式（I）化合物的药物组合物、制备式（I）化合物的工艺以及治疗炎症性疾病的治疗方法。
• Imidazopyridine derivatives
  申请人：Gilead Sciences, Inc.

  公开号：US11174256B2

  公开（公告）日：2021-11-16

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

  本公开提供了一种式 (I) 的化合物： 或其药学上可接受的盐。本公开还提供了包含式（I）化合物的药物组合物、制备式（I）化合物的工艺以及治疗炎症性疾病的治疗方法。
• Selective Phenylimidazole-Based Inhibitors of the <i>Mycobacterium tuberculosis</i> Proteasome
  作者：Wenhu Zhan、Hao-Chi Hsu、Trevor Morgan、Tierra Ouellette、Kristin Burns-Huang、Ryoma Hara、Adrian G. Wright、Toshihiro Imaeda、Rei Okamoto、Kenjiro Sato、Mayako Michino、Manoj Ramjee、Kazuyoshi Aso、Peter T. Meinke、Michael Foley、Carl F. Nathan、Huilin Li、Gang Lin

  DOI：10.1021/acs.jmedchem.9b01187

  日期：2019.10.24

  Proteasomes of pathogenic microbes have become attractive targets for anti-infectives. Coevolving with its human host, Mycobacterium tuberculosis (Mtb) has developed mechanisms to resist host-imposed nitrosative and oxidative stresses. Genetic deletion or pharmacological inhibition of the Mtb proteasome (Mtb20S) renders nonreplicating Mtb susceptible to reactive nitrogen species in vitro and unable to survive in the lungs of mice, validating the Mtb proteasome as a promising target for anti-Mtb agents. Using a structure-guided and flow chemistry-enabled study of structure-activity relationships, we developed phenylimidazole-based peptidomimetics that are highly potent for Mtb20S. X-ray structures of selected compounds with Mtb20S shed light on their selectivity for mycobacterial over human proteasomes.
• QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS
  申请人：GILEAD SCIENCES, INC.

  公开号：EP3873884A1

  公开（公告）日：2021-09-08